The estimated Net Worth of Management Ltd Abingworth is at least $115 Миллион dollars as of 4 May 2012. Management Abingworth owns over 1,100,000 units of Supernus Pharmaceuticals Inc stock worth over $111,888,000 and over the last 21 years Management sold SUPN stock worth over $3,026,022.
Management has made over 5 trades of the Supernus Pharmaceuticals Inc stock since 2004, according to the Form 4 filled with the SEC. Most recently Management bought 1,100,000 units of SUPN stock worth $5,500,000 on 4 May 2012.
The largest trade Management's ever made was buying 1,100,000 units of Supernus Pharmaceuticals Inc stock on 4 May 2012 worth over $5,500,000. On average, Management trades about 283,861 units every 483 days since 2004. As of 4 May 2012 Management still owns at least 3,600,000 units of Supernus Pharmaceuticals Inc stock.
You can see the complete history of Management Abingworth stock trades at the bottom of the page.
Management's mailing address filed with the SEC is 38 Jermyn St, St. James's, London SW1Y 6DT, UK.
Over the last 13 years, insiders at Supernus Pharmaceuticals Inc have traded over $37,265,765 worth of Supernus Pharmaceuticals Inc stock and bought 16,600,700 units worth $83,216,588 . The most active insiders traders include Forest Baskett, Scott D Sandell и Peter J Barris. On average, Supernus Pharmaceuticals Inc executives and independent directors trade stock every 30 days with the average trade being worth of $4,263,834. The most recent stock trade was executed by Jack A. Khattar on 3 September 2024, trading 21,000 units of SUPN stock currently worth $652,680.
pioneering new medicines in neurology and psychiatry with more than 20 years of experience, we are a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (cns) disorders. in 2013 we launched oxtellar xr® and trokendi xr®, two novel neurology products for the treatment of epilepsy. we are also developing several product candidates in psychiatry to address unmet medical needs and opportunities in attention-deficit hyperactivity disorder (adhd) and its coexisting disorders, and depression. we are developing differentiated products by leveraging our proprietary and in-licensed technologies. we use such technologies to discover and develop novel uses for known drug compounds and to enhance their therapeutic benefits. our focus on known drug compounds with established mechanisms of action reduces the risks, costs, and time typically associated with pharmaceutical product development.
Supernus Pharmaceuticals Inc executives and other stock owners filed with the SEC include: